Non Alcoholic Fatty Liver Disease Clinical Trial
Official title:
Serum Pentraxin-3 in Non-alcoholic Fatty Liver Disease With or Without Hepatitis C Virus: A Comparative Egyptian Study
Verified date | September 2017 |
Source | Ain Shams University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
This study included 70 subjects divided into 3 groups. Group I included 25 patients with NAFLD. Group II included 25 patients with NAFLD and chronic HCV. Group III: included 20 controls. Abdominal ultrasound was done to patients and controls. Plasma pentraxin-3 (PTX3) was measured using ELISA. Comparison between three groups was done regarding plasma pentraxin-3. Higher levels of plasma PTX3 were detected in NAFLD patients irrespective of presence or absence of chronic HCV infection. Plasma PTX3 could be used as a non-invasive test for prediction of metabolic syndrome in the high-risk population with high sensitivity and moderate specificity.
Status | Completed |
Enrollment | 70 |
Est. completion date | July 30, 2016 |
Est. primary completion date | April 15, 2016 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | N/A and older |
Eligibility |
Inclusion Criteria: - Patients with NAFLD. - Patients with NAFLD and chronic hepatitis C viral infection. Exclusion Criteria: - Current or past consumption of significant amount of alcohol more than 21 drinks and 14 drinks per week for men and women respectively. - Patients receiving Drugs which cause fatty liver as amiodarone, diliazem, tamoxifen, steroids. - Patients who take statins as it has lowering effect on plasma PTX3. - Patients having any clinical evidence of hepatic decompensation, such as hepatic encephalopathy, ascites, variceal bleeding, elevated serum bilirubin level to more than two folds the upper limit of normal. - Patients with heart failure. - Patients with autoimmune rheumatic disease. - Patients with chronic kidney diseases. - Patients with sepsis. |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Ain Shams University |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Plasma pentraxin-3 as a non invasive diagnostic marker in diagnosis of NAFLD in comparison to it's levels in patients with NAFLD and chronic hepatitis C viral infection | Measurement of plasma pentraxin-3 in patients with NAFLD in comparison to it's levels in patients with hepatic steatosis on top of HCV and normal controls | 1 year |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT02248311 -
"Preventing Cardiovascular Ischemic Events and Arresting Their Consequences in Type 2 Diabetic Population
|
N/A | |
Completed |
NCT01277237 -
The Effect Of Omega-3 Fatty Acids on Non-alcoholic Fatty Liver Disease
|
Phase 3 | |
Active, not recruiting |
NCT04442620 -
Prevention and Reversion of NAFLD in Obese Patients With Metabolic Syndrome by Mediterranean Diet and Physical Activity
|
N/A | |
Completed |
NCT01999101 -
Safety Pilot Study of Farnesoid X Receptor (FXR) Agonist in Non-alcoholic Fatty Liver Disease (NAFLD) Patients
|
Phase 2 | |
Completed |
NCT01327443 -
Exercise Versus Diet in the Treatment of Nonalcoholic Fatty Liver Disease
|
N/A | |
Active, not recruiting |
NCT01482065 -
The Sleep, Liver Evaluation and Effective Pressure Study
|
N/A | |
Completed |
NCT03135873 -
Mastiha Treatment for Obese With NAFLD Diagnosis
|
N/A | |
Completed |
NCT02686476 -
Effect of Empagliflozin on Liver Fat Content in Patients With Type 2 Diabetes
|
N/A | |
Completed |
NCT02820285 -
Characterization of Immune Semaphorin in Non Alcoholic Fatty Liver Disease and NASH
|
N/A | |
Completed |
NCT01556113 -
Genetic Effect on Omega 3 Fatty Acids for the Treatment of Fatty Liver Disease
|
N/A | |
Recruiting |
NCT06080386 -
UDFF Performance Evaluation ((Ultrason Derived Fat Fraction)
|
||
Terminated |
NCT02134522 -
The Role of Obstructive Sleep Apnea in Children With Fatty Liver Disease
|
N/A | |
Completed |
NCT01553500 -
Glucomannan Effects on Children With Non-alcoholic Fatty Liver Disease
|
Phase 2 | |
Completed |
NCT05426382 -
A Digital Solution for Individuals With Non Alcoholic Fatty Liver Disease
|
N/A | |
Completed |
NCT03300661 -
Non Alcoholic Fatty Liver Disease: Nutritional Epidemiology and Lifestyle Medicine
|
N/A | |
Not yet recruiting |
NCT02178839 -
The Effect of Oral β- Glucan Supplement on Appetite and Insulin Resistance in Non Alcoholic Fatty Liver Disease
|
N/A | |
Recruiting |
NCT02038387 -
Prospective Clinical Study of the Role of the Immune Response, in Relation to Diet, in Patients Affected by Either Chronic Hepatitis C Virus (HCV) Infection or Non Alcoholic Fatty Liver Disease (NAFLD)
|
N/A | |
Completed |
NCT01874249 -
Non Invasive Assessment of Liver Fibrosis in Fatty Liver Disease
|
N/A | |
Completed |
NCT01634048 -
The Effect of Protein-enriched Diet on Body Composition and Appetite
|
N/A | |
Completed |
NCT01966627 -
Genetics of Fatty Liver Disease in Children
|
N/A |